Clinical Trials Directory

Trials / Unknown

UnknownNCT05549869

Assessment of Serum Leptin in Vitiligo Patients

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
400 (estimated)
Sponsor
Sohag University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Evaluation of serum leptin in vitiligo patients and control Assessing its correlation to the body mass index and disease dermographic data .

Detailed description

, leptin is supposed to contribute to vitiligo pathogenesis through promoting the release of pro-inflammatory mediators such as tumor necrosis factor α "TNF," IL-2 and IL-6, as well as enhancing cytotoxic T cells "CD8" recruitment and inhibiting the functions of regulatory T cells "Tregs". Leptin can also aid in induction of oxidative stress by activating nicotinamide adenine dinucleotide phosphate (NADPH) oxidase• Venous blood samples will be taken from patients and controls to evaluate serum leptin: Morning samples will be taken after 12-h overnight fast in plain vacutainer tubes and directly centrifuged (1098 g for 15 min). * Sera will be then collected in plain, capped, 5 ml centrifuge tubes "Eppendorf" and freezed at -20ᵒC in a well-monitored freezer until the analysis is performed• Serum leptin will be quantitatively assessed in vitro using DRG leptin Sandwich Enzyme Linked Immuno-Sorbent Assay "ELISA". * ELISA will be performed according to manufacturer's guidelines where each run included a standard curve. * Using the mean absorbance value for each sample, the corresponding concentration from the standard curve will be determined.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTserum leptinEvaluation of serum leptin in vitiligo patients and control Assessing its correlation to the body mass index leptin is supposed to contribute to vitiligo pathogenesis through promoting the release of pro-inflammatory mediators

Timeline

Start date
2022-11-01
Primary completion
2023-09-01
Completion
2023-09-01
First posted
2022-09-22
Last updated
2022-09-22

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT05549869. Inclusion in this directory is not an endorsement.